122 results on '"Paris, Laura"'
Search Results
2. Vector control for malaria prevention during humanitarian emergencies: a systematic review and meta-analysis
3. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial
4. Foundations of hemophilia and epidemiology
5. Evaluating barriers to reaching women with public health information in remote communities in Mali.
6. Anticoagulation and Antiplatelet Regimen in Cardiac Transplant. Clinical Characteristics, Outcomes, and Blood Product Transfusion.
7. Humanistic burden of haemophilia A without inhibitors: A cross‐sectional analysis of the HemoLIFE study.
8. Evaluating barriers to reaching women with public health information in remote communities in Mali
9. Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma
10. A review of Musca sorbens(Diptera: Muscidae) and Musca domesticabehavior and responses to chemical and visual cues
11. Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial
12. The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma
13. P-034 Alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA × CD3 T-cell engager, in patients (pts) with relapsed/refractory multiple myeloma (RRMM): latest results from a phase 1 first-in-human clinical study
14. P895: DARATUMUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE (DPD) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND 17P DELETION: UPDATED ANALYSIS OF THE DEDALO PHASE II TRIAL
15. P883: ALNUCTAMAB (ALNUC; BMS-986349; CC-93269), A BCMA × CD3 T-CELL ENGAGER, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): LATEST RESULTS FROM A PHASE 1 FIRST-IN-HUMAN CLINICAL STUDY
16. When Cannabis sativa L. Turns Purple: Biosynthesis and Accumulation of Anthocyanins
17. Treating multiple myeloma in the era of new drugs: What is the right choice?
18. Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study
19. Dedalo: Phase II Study of Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Patients with Relapsed/Refractory Multiple Myeloma and 17p Deletion
20. Parasite clearance dynamics in children hospitalised with severe malaria in the Ho Teaching Hospital, Volta Region, Ghana
21. Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysis
22. High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
23. OAB-011: Predictors of unsustained negativity in minimal residual disease (MRD)-negative transplant-eligible newly diagnosed multiple myeloma (MM) patients enrolled in the FORTE trial
24. Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study
25. Vector Control for Malaria Prevention During Humanitarian Emergencies: A Systematic Review and Meta-Analysis
26. Real-World Patterns of Utilization and Outcome of Market Approved Lenalidomide-Based Triplet Combinations in First Relapsed Multiple Myeloma Patients: Evidence from a Propensity Score Matched Analysis
27. Safety of outpatient stem cell mobilization with low‐ or intermediate‐dose cyclophosphamide in newly diagnosed multiple myeloma patients
28. Additional file 1 of Covid-19 and gender: lower rate but same mortality of severe disease in women—an observational study
29. Additional file 2 of Covid-19 and gender: lower rate but same mortality of severe disease in women—an observational study
30. A Rare Case of Atypical Palatal‐Lingual Tremor Associated with Waldenström's Macroglobulinemia
31. Predicting in-hospital mortality from Coronavirus Disease 2019: A simple validated app for clinical use
32. The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma
33. Real-Rd - Real Life Italian Experience with Lenalidomide and Low-Dose Dexamethasone (Rd) As First Line Treatment of Newly-Diagnosed Multiple Myeloma Patients Not Eligible to Stem Cell Transplantation: Outcomes and Tolerability
34. Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial
35. Newly-Diagnosed, Non-Transplant Eligible Multiple Myeloma Patients: Determinants of Choice of First-Line Treatment in a Single-Center
36. First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials
37. Effect of novel agents on the risk of early death of newly diagnosed symptomatic multiple myeloma patients: A single Centre retrospective analysis
38. Introduzione
39. Anselmo Bucci, Carlo Wostry, Giuseppe Furlani: tre interpreti della 'Finis Austriae'
40. Guida al Lascito Antonio Fonda Savio
41. Salvage Autologous Stem Cell Transplant for the Treatment of First Relapse Multiple Myeloma: Evidence of Its Clinical Role from a Multicenter Italian Study
42. Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study
43. Impact of the Addition of Daratumumab to the Standard Bortezomib-Thalidomide-Dexamethasone Regimen on Hematopoietic Stem Cell Mobilization and Collection, Post-Transplant Engraftment and Infectious Complications: A Case-Control Multicentre Real-Life Analysis
44. CAMMA 2: A phase I/II trial evaluating the efficacy and safety of cevostamab in patients with relapsed/refractory multiple myeloma (RRMM) who have triple-class refractory disease and have received a prior anti-B-cell maturation antigen (BCMA) agent.
45. Effect of novel agents on the risk of early death of newly diagnosed symptomatic multiple myeloma patients: A single Centre retrospective analysis.
46. Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma
47. Outpatient Stem Cell Mobilization with Low and Intermediate Dose Cyclophosphamide Is a Safe and Effective Procedure in Newly Diagnosed Multiple Myeloma Patients Eligible for Stem Cell Transplantation
48. A Randomized Study of Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Cyclophosphamide-Dexamethasone Induction in Newly Diagnosed Myeloma Patients Eligible for Transplant: High Efficacy in High- and Standard-Risk Patients
49. Effect of Proteasome Inhibitors and/or Immunomodulatory Drugs on the Risk of Early Death of 991 Newly Diagnosed Symptomatic Multiple Myeloma Patients: A Single Centre Retrospective Analysis
50. Lucie Borleteau: le vent en poupe.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.